[메디칼업저버 손형민 기자] Lilly Korea (CEO Alberto Riva) announced on the 3rd that the health insurance benefit standard for Olumiant (ingredient name: baricitinib) has been expanded as a treatment for chronic severe atopic dermatitis for adults from May 1.
Olumiant received approval from the Ministry of Food and Drug Safety in May 2021 as the first JAK inhibitor to treat moderate to severe atopic dermatitis.
With this revision of the reimbursement standards, Olumiant is now eligible to receive health insurance benefits for indications for atopic dermatitis following the existing rheumatoid arthritis.
Olumiant confirmed a significant efficacy and safety profile through clinical trials in adult patients diagnosed with moderate to severe atopic dermatitis who had an insufficient response to topical corticosteroids (TCS).
The patients treated with Olumiant plus TCS showed a significant improvement in vIGA-AD 0 or 1 (clear or near clear skin symptoms) of up to 31% at 16 weeks compared to the control group.
In addition, it was effective in improving symptoms of itchiness, which is one of the difficulties experienced by patients.
In the patient outcome report (PRO), the improvement in itch severity was significant in patients treated with Olumiant and TCS in combination from the second day of treatment.
It was confirmed that the evaluation index for the patient’s sleep ability and the evaluation index for the degree of waking during sleep also improved significantly from the second day of treatment.
Lilly Korea said, “Through this reimbursement, we can provide Olumiant, a new oral treatment option, to more patients.”
